Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Cited In for PubMed (Select 18227347)

1.

The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NFκB inhibitor.

Ruiz-Lafuente N, Alcaraz-García MJ, Sebastián-Ruiz S, Gómez-Espuch J, Funes C, Moraleda JM, García-Garay MC, Montes-Barqueros N, Minguela A, Álvarez-López MR, Parrado A.

PLoS One. 2014 Oct 3;9(10):e109533. doi: 10.1371/journal.pone.0109533. eCollection 2014.

2.

Anti-cancer activity of carbamate derivatives of melampomagnolide B.

Janganati V, Penthala NR, Madadi NR, Chen Z, Crooks PA.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3499-502. doi: 10.1016/j.bmcl.2014.05.059. Epub 2014 May 27.

PMID:
24928404
3.

STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis.

Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z.

Mol Cancer Res. 2014 Sep;12(9):1267-82. doi: 10.1158/1541-7786.MCR-13-0652-T. Epub 2014 May 16.

PMID:
24836891
4.

The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.

Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, Danilov AV.

Clin Cancer Res. 2014 Mar 15;20(6):1576-89. doi: 10.1158/1078-0432.CCR-13-0987.

5.

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV.

Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Review.

6.

B cell receptor signaling in chronic lymphocytic leukemia.

Burger JA, Chiorazzi N.

Trends Immunol. 2013 Dec;34(12):592-601. doi: 10.1016/j.it.2013.07.002. Epub 2013 Aug 5. Review.

7.

Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Foà R, Del Giudice I, Guarini A, Rossi D, Gaidano G.

Haematologica. 2013 May;98(5):675-85. doi: 10.3324/haematol.2012.069369. Review.

8.

Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.

Garding A, Bhattacharya N, Claus R, Ruppel M, Tschuch C, Filarsky K, Idler I, Zucknick M, Caudron-Herger M, Oakes C, Fleig V, Keklikoglou I, Allegra D, Serra L, Thakurela S, Tiwari V, Weichenhan D, Benner A, Radlwimmer B, Zentgraf H, Wiemann S, Rippe K, Plass C, Döhner H, Lichter P, Stilgenbauer S, Mertens D.

PLoS Genet. 2013 Apr;9(4):e1003373. doi: 10.1371/journal.pgen.1003373. Epub 2013 Apr 4.

9.

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.

Efremov DG, Wiestner A, Laurenti L.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012067. doi: 10.4084/MJHID.2012.067. Epub 2012 Oct 9.

10.

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A.

BMC Cancer. 2012 Oct 16;12:478. doi: 10.1186/1471-2407-12-478.

11.

Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.

Melarangi T, Zhuang J, Lin K, Rockliffe N, Bosanquet AG, Oates M, Slupsky JR, Pettitt AR.

Cell Death Dis. 2012 Aug 16;3:e372. doi: 10.1038/cddis.2012.102.

12.

TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q.

Garding A, Bhattacharya N, Haebe S, Müller F, Weichenhan D, Idler I, Ickstadt K, Stilgenbauer S, Mertens D.

Haematologica. 2013 Feb;98(2):269-73. doi: 10.3324/haematol.2012.070623. Epub 2012 Aug 8.

13.

The B-cell receptor signaling pathway as a therapeutic target in CLL.

Woyach JA, Johnson AJ, Byrd JC.

Blood. 2012 Aug 9;120(6):1175-84. doi: 10.1182/blood-2012-02-362624. Epub 2012 Jun 19. Review.

15.

Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.

Palazzo AL, Evensen E, Huang YW, Cesano A, Nolan GP, Fantl WJ.

PLoS One. 2011;6(10):e24592. doi: 10.1371/journal.pone.0024592. Epub 2011 Oct 10.

16.

NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.

Hunter JE, Willmore E, Irving JA, Hostomsky Z, Veuger SJ, Durkacz BW.

Oncogene. 2012 Jan 12;31(2):251-64. doi: 10.1038/onc.2011.229. Epub 2011 Jun 27.

17.

MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.

Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, Neuberg D, Wucherpfennig KW, Brown JR, Novina CD.

PLoS One. 2011 Mar 8;6(3):e16956. doi: 10.1371/journal.pone.0016956.

18.

STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.

Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z.

Mol Cancer Res. 2011 Apr;9(4):507-15. doi: 10.1158/1541-7786.MCR-10-0559. Epub 2011 Mar 1.

19.

Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males.

Marteau JB, Rigaud O, Brugat T, Gault N, Vallat L, Kruhoffer M, Orntoft TF, Nguyen-Khac F, Chevillard S, Merle-Beral H, Delic J.

BMC Med Genomics. 2010 Nov 10;3:53. doi: 10.1186/1755-8794-3-53.

20.

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.

Blood. 2011 Jan 13;117(2):563-74. doi: 10.1182/blood-2010-05-284984. Epub 2010 Oct 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk